BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsCompany update

CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 13, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific

Related news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

OKYOOKYO Pharma2026-05-19 11:00 EST

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

OKYOOKYO Pharma2026-04-07 11:00 EST

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

PRQRProQR Therapeutics2026-04-08 12:00 EST

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

OCGNOcugen2026-05-13 11:02 EST

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

PRQRProQR Therapeutics2026-05-11 12:00 EST

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-07-13 12:00 EST

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTXLineage Cell Therapeutics2026-05-12 20:01 EST

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
1.13 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States